Fas/FasL interaction: a novel immune therapy approach with immobilized biologicals.
Systemically applied agents to modulate the Fas/FasL system, e.g., by stimulation of Fas on activated leukocytes or tumor cells failed as strategies in immune therapy due to severe toxic effects in the host. Recently, a novel strategy has been developed by using immobilized immune active biologicals in a medical device that may allow immune management without expensive systemic therapy. This review reports on the potential role of Fas/FasL in immune therapy and summarizes current experimental and clinical data with the leukocyte inhibition module (LIM), an immobilized anti-Fas antibody containing device yet used in extracorporeal blood circulation. This proof of principal may stimulate the development of other devices based on the regulation of Fas/FasL or other targets relevant for immune disorders.
Scholz
Martin
M
Institute of Medical Virology, Johann Wolfgang Goethe University, Frankfurt am Main, Germany. m.scholz@em.uni-frankfurt.de
Cinatl
Jindrich
J
D000818:Animals; D017209:Apoptosis; D001327:Autoimmune Diseases / Q000276:immunology; D002315:Cardiopulmonary Bypass / Q000009:adverse effects; D004864:Equipment and Supplies; D053222:Fas Ligand Protein; D006801:Humans; D007075:Immunoglobulin M / Q000378:metabolism*; D016209:Interleukin-8 / Q000502:physiology; D016399:Lymphoma, T-Cell / Q000276:immunology; D008562:Membrane Glycoproteins / Q000037:antagonists & inhibitors* / Q000276:immunology / Q000502:physiology; D014777:Virus Diseases / Q000276:immunology; D019014:fas Receptor / Q000502:physiology*
C505661:FASLG protein, human; D053222:Fas Ligand Protein; D007075:Immunoglobulin M; D016209:Interleukin-8; D008562:Membrane Glycoproteins; D019014:fas Receptor